================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): NOVEMBER 16, 2006
CIPHERGEN BIOSYSTEMS, INC.
(Exact name of Registrant as specified in its charter)
Delaware 000-31617 33-059-5156
(State or other jurisdiction of (Commission (I.R.S. Employer
incorporation or organization) File Number) Identification Number)
6611 Dumbarton Circle
Fremont, CA 94555
(Address of principal executive offices)
(510) 505-2100 (Registrant's
telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the Registrant under any of the
following provisions (see General Instruction A.2 below):
[ ] Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
================================================================================
ITEM 7.01 REGULATION FD DISCLOSURE.
On November 16, 2006, the Company issued a press release announcing the
completion of the exchange of outstanding convertible senior notes with certain
holders. A copy of this press release is also furnished as Exhibit 99.1 to this
report.
The information contained in this Form 8-K shall not be deemed "filed"
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended
(the "Exchange Act"), or incorporated by reference in any filing under the
Securities Act of 1933, as amended, or the Exchange Act, except as shall be
expressly set forth by specific reference in such a filing.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.
(d) Exhibits
99.1 Press release of Ciphergen Biosystems, Inc., dated November 16, 2006
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Ciphergen Biosystems, Inc.
(Registrant)
Date: November 16, 2006 By: /s/ Gail S. Page
-------------------------------------
Gail S. Page
President and Chief Executive Officer
3
EXHIBIT INDEX
Exhibit
Number Description
--------- --------------------------------------------------------------------
99.1 Press release of Ciphergen Biosystems, Inc. dated November 16, 2006
4